| 8.5 0.01 (0.12%) | 09-25 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.92 | 1-year : | 11.59 |
| Resists | First : | 8.5 | Second : | 9.92 |
| Pivot price | 8.45  |
|||
| Supports | First : | 8.41 | Second : | 8.36 |
| MAs | MA(5) : | 8.48 |
MA(20) : | 8.44 |
| MA(100) : | 7.59 |
MA(250) : | 5.95 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 96.6 |
D(3) : | 88.8 |
| RSI | RSI(14): 76.4 | |||
| 52-week | High : | 8.5 | Low : | 3.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LMNL ] has closed below upper band by 13.8%. Bollinger Bands are 84.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.5 - 8.55 | 8.55 - 8.58 |
| Low: | 8.4 - 8.44 | 8.44 - 8.48 |
| Close: | 8.43 - 8.5 | 8.5 - 8.56 |
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Tue, 26 Sep 2023
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP - Stock Titan
Tue, 19 Sep 2023
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP - PR Newswire
Wed, 05 Apr 2023
Just the rockets please ? - RagingBull
Thu, 21 Jul 2022
Liminal BioSciences Announces Discontinuation of Fezagepras Development - PR Newswire
Tue, 25 Aug 2020
Stock Market News for Aug 25, 2020 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.26e+006 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.147e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 267.4 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 502.6 % |
| Return on Equity (ttm) | -39 % |
| Qtrly Rev. Growth | 492000 % |
| Gross Profit (p.s.) | -0.98 |
| Sales Per Share | -4.84 |
| EBITDA (p.s.) | -507839 |
| Qtrly Earnings Growth | -6.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.76 |
| Price to Cash Flow | 37.72 |
| Dividend | 0 |
| Forward Dividend | 675 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|